Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.

As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Decision puts spotlight on Lord Hermer, who represented the former Sinn Fein leader in a separate compensation case ...

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...